Recovery from anti-recombinant-human-erythropoietin associated pure red cell aplasia in end-stage renal disease patients after renal transplantation
Authors:
- K. PraditpornsilpaKPK. Praditpornsilpa
- S. BuranasotSBS. Buranasot
- N. BhokaisuwanNBN. Bhokaisuwan
- Y. AvihingsanonYAY. Avihingsanon
- T. PisitkulTPT. Pisitkul
- T. KansanabuchTKT. Kansanabuch
- S. Eiam-OngSES. Eiam-Ong
- S. ChusilSCS. Chusil
- T. IntarakumtornchaiTIT. Intarakumtornchai
- K. TungsangaKTK. Tungsanga
- 25 February 2005
- journal article
- case report
- Published by Oxford University Press (OUP) in Nephrology Dialysis Transplantation
- Vol. 20 (3) , 626-630
Abstract
No abstract availableThis publication has 5 references indexed in Scilit:
- Pure Red-Cell Aplasia and Epoetin TherapyNew England Journal of Medicine, 2004
- Pure Red-Cell Aplasia and Antierythropoietin Antibodies in Patients Treated with Recombinant ErythropoietinNew England Journal of Medicine, 2002
- Rapid Method for Detection of Anti-Recombinant Human Erythropoietin Antibodies as a New Form of Erythropoietin ResistanceClinical Chemistry, 1997
- Resistance to ErythropoietinNew England Journal of Medicine, 1996
- Improved Plasma Culture System for Production of Erythrocytic Colonies In Vitro: Quantitative Assay Method for CFU-EBlood, 1974